

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing of claims in the application:

Listing of Claims

Claims 1-35. (Cancelled)

Claim 36. (Currently Amended) Isolated microbicidal peptide which exhibits bactericidal and/or fungicidal activity having an amino acid sequence consisting ~~essentially~~ of the amino acid sequence of TC-1 as given in Figure 1 (**SEQ ID NO: 12**), optionally with the following modifications:

(a) at least the two C-terminal amino acids alanine and aspartic acid are removed;
and/or

(b) the peptide is provided with an N-terminal His-tag-containing sequence.

Claim 37. (Previously Presented) Isolated peptide as claimed in claim 36, wherein the amino acid sequence of TC-1 is extended at its N-terminus with at least one of the following selections of amino acids, given from N-terminus to C-terminus:

(a) one or more of the 17 N-terminal amino acids of TC-2 in the sequence as given in Figure 1 (**SEQ ID NO: 6**); or

(b) a methionine; or

(c) a tyrosine; or

(d) a methionine and one or more of the 17 N-terminal amino acids of TC-2 in the sequence as given in Figure 1 (**SEQ ID NO: 6**); or

(e) a methionine and a tyrosine; or

(f) a methionine and a tyrosine and one or more of the N-terminal amino acids of TC-2 in the sequence as given in Figure 1 (**SEQ ID NO: 6**),

wherein, in the case in which a His-tag containing sequence is present, this sequence is located N-terminally of the peptides as defined in (e) or (f).

Claim 38. (Previously Presented) Isolated microbicial peptide according to claim 36, wherein the peptide is thrombocidin-1 (TC-1) as depicted in Figure 1 (SEQ ID NO:12).

Claim 39. (Withdrawn)

Claim 40. (Previously Presented) Isolated microbicial peptide according to claim 37, wherein the peptide is thrombocidin-2 (TC-2) as depicted in Figure 1 (SEQ ID NO: 6).

Claims 41-47. (Withdrawn)

Claim 48. (Cancelled)

Claim 49. (Previously Presented) Isolated microbicial peptide according to claim 36, wherein said peptide exhibits bactericidal activity against at least one of *Escherichia coli*, *Bacillus subtilis*, *Streptococcus sanguis*, *Streptococcus pneumoniae*, *Staphylococcus epidermis*, and *Staphylococcus aureus*.

Claim 50. (Cancelled)

Claim 51. (Previously Presented) Isolated microbicial peptide according to claim 36, wherein said peptide exhibits fungicidal activity against at least one of *Candida albicans*, *C. glabrata*, *Cryptococcus neoformans*, *Aspergillus flavus*, *A. fumigatus*, and *Pseudoallescheria spec.*

Claim 52. (Previously Presented) Isolated microbicial peptide having an amino acid sequence that is at least 70% homologous to the amino acid sequence of peptides according to claim 36.

Application No. 09/509,391
Paper Dated: March 17 2004
In Reply to USPTO Correspondence of November 18, 2003
Attorney Docket No. 0702-000648

Claim 53. (Previously Presented) Isolated microbicidal peptide having an amino acid sequence that is at least 80% homologous to the amino acid sequence of peptides according to claim 36.

Claim 54. (Previously Presented) Isolated microbicidal peptide having an amino acid sequence that is at least 90% homologous to the amino acid sequence of peptides according to claim 36.

Claim 55. (Previously Presented) Isolated microbicidal peptide having an amino acid sequence that is at least 95% homologous to the amino acid sequence of peptides according to claim 36.

Claim 56. (Previously Presented) Method for the treatment of at least one of bacterial infection and fungal infection in humans and animals, comprising administering an isolated microbicidal peptide according to claim 36.

Claim 57. (previously added): The method of claim 56, wherein the infection is endocarditis.

Claims 58-61. (withdrawn)